|
| 37943166 | Effects of KRAS Genetic Interactions on Outcomes in Cancers of the Lung, Pancreas, and Colorectum. | Cancer Epidemiol Biomarkers Prev | 2024 |
| 37748191 | MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling. | Mol Cancer Ther | 2024 |
| 36326731 | Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19. | JAMA Oncol | 2023 |
| 37487667 | Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study. | J Immunother Cancer | 2023 |
| 37589215 | Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer. | Oncologist | 2023 |
| 37644967 | Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced <i>ALK</i>-Â or <i>ROS1</i>-Rearranged NSCLC: A Brief Report. | JTO Clin Res Rep | 2023 |
| 37673108 | Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2023 |
| 37084736 | Genomic mapping of metastatic organotropism in lung adenocarcinoma. | Cancer Cell | 2023 |
| 37384866 | Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced <i>KRAS G12C</i>-Mutant Non-Small Cell Lung Cancer. | JCO Precis Oncol | 2023 |
| 37182602 | Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification. | J Thorac Oncol | 2023 |
| 37015337 | NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. | J Natl Compr Canc Netw | 2023 |
| 37279096 | Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients. | Clin Cancer Res | 2023 |
| 37270692 | Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Non-Small-Cell Lung Cancer. | J Clin Oncol | 2023 |
| 37302348 | COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease. | Transl Oncol | 2023 |
| 37433095 | Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.2. | J Clin Oncol | 2023 |
| 37432985 | Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. | Clin Cancer Res | 2023 |
| 37223888 | The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non-Small Cell Lung Cancer. | Clin Cancer Res | 2023 |
| 36889516 | Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis. | Int J Radiat Oncol Biol Phys | 2023 |
| 36871392 | Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. | ESMO Open | 2023 |
| 36871345 | Conventional and radiomic features to predict pathology in the preoperative assessment of anterior mediastinal masses. | Lung Cancer | 2023 |
| 36537204 | Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for <i>EGFR</i> exon 20 insertion-positive non-small cell lung cancer. | Expert Rev Anticancer Ther | 2023 |
| 36534938 | Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2. | J Clin Oncol | 2023 |
| 36729110 | Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas. | Clin Cancer Res | 2023 |
| 36528430 | Clinicopathologic outcomes of preoperative targeted therapy in patients with clinical stage I to III non-small cell lung cancer. | J Thorac Cardiovasc Surg | 2023 |
| 36494075 | Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers. | J Thorac Oncol | 2023 |
| 36355783 | Molecular Characterization of Acquired Resistance to KRASG12C-EGFR Inhibition in Colorectal Cancer. | Cancer Discov | 2023 |
| 34561242 | <i>Smarca4</i> Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung. | Cancer Discov | 2022 |
| 35511917 | Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data. | Clin Cancer Res | 2022 |
| 35545176 | Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 |
| 35767426 | Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer. | Clin Cancer Res | 2022 |
| 35460914 | One committee to review it all: A single, multi-disciplinary COVID-19 research committee. | Contemp Clin Trials | 2022 |
| 35816668 | Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline. | J Clin Oncol | 2022 |
| 35816666 | Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline. | J Clin Oncol | 2022 |
| 35658005 | Adagrasib in Non-Small-Cell Lung Cancer Harboring a <i>KRAS<sup>G12C</sup></i> Mutation. | N Engl J Med | 2022 |
| 35810553 | Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study. | Eur J Cancer | 2022 |
| 36614913 | Mobocertinib (TAK-788) in <i>EGFR</i> Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort. | J Clin Med | 2022 |
| 35875467 | Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced <i>ALK</i>-Positive NSCLC. | JTO Clin Res Rep | 2022 |
| 36074020 | Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers. | Cancer Res | 2022 |
| 36357680 | Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. | Nat Med | 2022 |
| 36301585 | Clinical Trial Participation Among Older Adult Medicare Fee-for-Service Beneficiaries With Cancer. | JAMA Oncol | 2022 |
| 36166047 | Serplulimab With Chemotherapy in Extensive-Stage SCLC. | JAMA | 2022 |
| 35952318 | SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors. | JCO Precis Oncol | 2022 |
| 33844992 | CT Radiomic Features for Predicting Resectability and TNM Staging in Thymic Epithelial Tumors. | Ann Thorac Surg | 2022 |
| 35192403 | A Scalable Quality Assurance Process for Curating Oncology Electronic Health Records: The Project GENIE Biopharma Collaborative Approach. | JCO Clin Cancer Inform | 2022 |
| 34918546 | Encorafenib plus binimetinib in patients with <i>BRAF</i><sup>V600</sup>-mutant non-small cell lung cancer: phase II PHAROS study design. | Future Oncol | 2022 |
| 35315914 | Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation. | JAMA Netw Open | 2022 |
| 35149545 | MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer. | Mol Cancer Res | 2022 |
| 34963703 | Immune biomarkers and response to checkpoint inhibition of BRAF<sup>V600</sup> and BRAF non-V600 altered lung cancers. | Br J Cancer | 2022 |
| 34734967 | Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies. | JAMA Oncol | 2022 |
| 34486558 | The Use of Sunitinib as Maintenance Therapy in a Pediatric Patient With a Poorly Differentiated Thymic Carcinoma. | J Pediatr Hematol Oncol | 2022 |